Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.46 |
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.39 |
| ▸ | TACR1 | P25103 | 4/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL581040 | 0.88 | TACR1 (0.47) | NOTUMIDH2TACR1FFAR4 | |
| SCHEMBL580684 | 0.88 | NOTUM (0.42) | NOTUMIDH2SLC6A9TACR1MEN1 | |
| SCHEMBL3086468 | 0.85 | NOTUM (0.42) | NOTUMSLC6A9TACR1HSD11B1 | |
| SCHEMBL582014 | 0.83 | NOTUM (0.43) | NOTUMHSD11B1KMT2A | |
| SCHEMBL586675 | 0.83 | FFAR4 (0.50) | NOTUMFFAR4HSD11B1 | |
| SCHEMBL581556 | 0.82 | NOTUM (0.53) | NOTUMIDH2SLC6A9POLBHSD11B1 | |
| SCHEMBL581657 | 0.81 | NOTUM (0.52) | NOTUMSLC6A9POLBCYP2C9CYP2C19 | |
| SCHEMBL3075498 | 0.81 | NOTUM (0.37) | NOTUMCYP2C19TSHR | |
| SCHEMBL587743 | 0.79 | MAPT (0.41) | SLC6A9TACR1MEN1TSHRKMT2A | |
| SCHEMBL581119 | 0.77 | NOTUM (0.43) | NOTUMIDH2TACR1FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | NOTUM 2559/4885IDH2 829/4885SLC6A9 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.